Business Context and Reporting Period
This Form 8-K, dated July 25, 2025, reports the completion of a merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals. Effective July 25, 2025, the combined entity changed its name to ImageneBio, Inc. (Ticker: IMA). The company is now a clinical-stage biopharmaceutical firm focused on immunological and inflammatory diseases, with its primary asset being IMG-007, an anti-OX40 monoclonal antibody for atopic dermatitis. The filing also details a 1-for-12 reverse stock split and a concurrent PIPE financing.
Key Financial Metrics and Capital Structure
- PIPE Financing: The company raised approximately $75.0 million in gross proceeds through the sale of 2,508,337 shares at approximately $29.90 per share.
- Share Count: Approximately 11,181,676 shares of common stock are outstanding immediately following the merger and PIPE financing (post-reverse stock split).
- Ownership Structure (Post-Merger/PIPE):
- Pre-Merger Inmagene Equityholders: ~43.5%
- Pre-Merger Ikena Equityholders: ~35.0%
- PIPE Investors: ~21.5%
- Divestiture Proceeds: Inmagene divested its non-IMG-007 assets to a new entity (SellCo) in exchange for a promissory note of $8.9 million. Payments on this note will be distributed to Inmagene CVR holders.
- Transition Services: The company paid $1.25 million as a pre-payment for transition services related to the IMG-007 program.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, net income, or operating cash flow figures for the combined entity in this report. Unaudited pro forma financial information is referenced in Exhibit 99.2 but not detailed in the text.
Material Changes and Transactions
- Merger Completion: Ikena Oncology, Inc. merged with Inmagene Biopharmaceuticals. Inmagene shareholders received 0.0030510 shares of Ikena Common Stock for each Inmagene share.
- Asset Divestiture: The "Non-OX40 Business" (all assets except IMG-007) was divested to Miragene Inc. (SellCo). Consequently, IMG-007 is the sole product candidate in clinical development.
- Contingent Value Rights (CVRs):
- Ikena CVRs: Issued to former Ikena shareholders for 100% of net proceeds from pre-merger asset dispositions (e.g., IK-595) and 90% of proceeds from dispositions within one year post-merger.
- Inmagene CVRs: Issued to former Inmagene shareholders for 100% of net proceeds from pre-merger dispositions of non-IMG-007 assets and 90% of proceeds from dispositions within one year post-merger.
- Corporate Actions: A 1-for-12 reverse stock split was effected. The ticker symbol changed from IKNA to IMA, and trading moved to the Nasdaq Capital Market.
Guidance, Outlook, and Risks
- Outlook: The company is advancing the ADAPTIVE Trial (Phase 2b) for IMG-007 in atopic dermatitis, with the first patient dosed on July 1, 2025.
- Management Commentary: The merger is intended to combine Ikena's capital resources with Inmagene's clinical-stage asset (IMG-007) to accelerate development.
- Risks and Contingencies:
- CVR Payments: There is no assurance that CVR holders will receive any payments if no proceeds are generated from asset dispositions.
- Litigation: Two shareholder lawsuits (Smith v. Ikena and Kent v. Ikena) were filed in New York Supreme Court alleging negligence and misleading disclosures regarding the merger. The company believes these claims are without merit.
- Forward-Looking Statements: Risks include the ability to raise capital, clinical trial outcomes, regulatory approvals, and the success of the IMG-007 program.
Important Facts for Investor Verification
- Cash Runway: Verify the company's total cash position post-merger (including the $75M PIPE) against its burn rate to determine the operational runway.
- CVR Valuation: Assess the likelihood of future milestone or royalty payments from the divested assets (IK-595 and non-IMG-007 assets) to determine the potential value of the CVRs.
- IMG-007 Progress: Monitor upcoming data readouts from the ADAPTIVE Phase 2b trial, as this is the company's sole clinical asset.
- Litigation Status: Track the status of the pending shareholder lawsuits regarding the merger disclosures.
- Executive Compensation: Review the specific severance and retention packages for departing executives (Mark Manfredi, Jonathan Jian Wang) and new hires (Kristin Yarema) to understand near-term cash outflows.